AR120232A1 - Un anticuerpo, una composición farmacéutica y un método - Google Patents
Un anticuerpo, una composición farmacéutica y un métodoInfo
- Publication number
- AR120232A1 AR120232A1 ARP200102851A ARP200102851A AR120232A1 AR 120232 A1 AR120232 A1 AR 120232A1 AR P200102851 A ARP200102851 A AR P200102851A AR P200102851 A ARP200102851 A AR P200102851A AR 120232 A1 AR120232 A1 AR 120232A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- antibody
- individual
- present
- c1r2s2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21042—Complement subcomponent C1s (3.4.21.42)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
Abstract
La presente se refiere a anticuerpos tales como anticuerpos anti-C1s, composiciones farmacéuticas que los comprenden y métodos para uso de estos. La presente proporciona anticuerpos que comprenden una región de unión a antígeno y una región constante de anticuerpo, presenta una función de desplazamiento de manera tal que el anticuerpo se une al complejo C1qrs y promueve la disociación de C1q del complejo C1qrs y/o una función de bloqueo, de manera tal que el anticuerpo se une a C1r2s2 e inhibe la unión de C1q a C1r2s2, y se une a C1s de una manera dependiente del pH. La presente proporciona además composiciones farmacéuticas que comprenden uno cualquiera de los anticuerpos y métodos para tratar a un individuo que presenta una enfermedad o un trastorno mediado por complemento, o para impedir que un individuo presente de manera potencial una enfermedad o trastorno mediado por complemento, que comprenden la administración de uno cualquiera de los anticuerpos al individuo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019189148 | 2019-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120232A1 true AR120232A1 (es) | 2022-02-09 |
Family
ID=75487729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102851A AR120232A1 (es) | 2019-10-16 | 2020-10-15 | Un anticuerpo, una composición farmacéutica y un método |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240092889A1 (es) |
| EP (1) | EP4045534A4 (es) |
| JP (1) | JP7628796B2 (es) |
| KR (1) | KR20220082698A (es) |
| CN (1) | CN114829604B (es) |
| AR (1) | AR120232A1 (es) |
| AU (1) | AU2020368745A1 (es) |
| BR (1) | BR112022006014A2 (es) |
| CA (1) | CA3153207A1 (es) |
| IL (1) | IL291557A (es) |
| MX (1) | MX2022003911A (es) |
| SG (1) | SG11202011647SA (es) |
| TW (1) | TWI856193B (es) |
| WO (1) | WO2021075479A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019098212A1 (en) | 2017-11-14 | 2019-05-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibodies and methods of use |
| BR112021021689A2 (pt) | 2019-05-15 | 2022-03-22 | Chugai Pharmaceutical Co Ltd | Molécula de ligação a antígeno, composição farmacêutica, e método |
| AR125344A1 (es) * | 2021-04-15 | 2023-07-05 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-c1s |
| JP7753313B2 (ja) * | 2022-10-18 | 2025-10-14 | 中外製薬株式会社 | 抗Ｃ１ｓ抗体の使用 |
| CN116990512B (zh) * | 2023-09-25 | 2023-12-08 | 聚诚(北京)生物科技有限责任公司 | 一种基质金属蛋白酶-9检测试剂盒 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009125825A1 (ja) | 2008-04-11 | 2009-10-15 | 中外製薬株式会社 | 複数分子の抗原に繰り返し結合する抗原結合分子 |
| EA037325B1 (ru) * | 2013-07-09 | 2021-03-12 | Аннексон, Инк. | Антитела против фактора комплемента c1q и их применения |
| US20180169240A1 (en) * | 2015-06-26 | 2018-06-21 | Bioverativ Usa Inc. | Methods of treating autoimmune and alloimmune disorders |
| RU2018130525A (ru) * | 2016-01-27 | 2020-02-27 | Цсл Беринг Ленгнау Аг | РЕКОМБИНАНТНЫЕ Fc-МУЛЬТИМЕРЫ IgG |
| WO2019098212A1 (en) * | 2017-11-14 | 2019-05-23 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibodies and methods of use |
| AU2019250403A1 (en) * | 2018-04-13 | 2020-11-19 | Chugai Seiyaku Kabushiki Kaisha | Anti-complement component antibodies and methods of use |
| BR112021021689A2 (pt) * | 2019-05-15 | 2022-03-22 | Chugai Pharmaceutical Co Ltd | Molécula de ligação a antígeno, composição farmacêutica, e método |
-
2020
- 2020-10-15 AR ARP200102851A patent/AR120232A1/es unknown
- 2020-10-15 KR KR1020207034988A patent/KR20220082698A/ko active Pending
- 2020-10-15 BR BR112022006014A patent/BR112022006014A2/pt not_active Application Discontinuation
- 2020-10-15 US US17/768,053 patent/US20240092889A1/en active Pending
- 2020-10-15 JP JP2020173697A patent/JP7628796B2/ja active Active
- 2020-10-15 AU AU2020368745A patent/AU2020368745A1/en not_active Withdrawn
- 2020-10-15 WO PCT/JP2020/038854 patent/WO2021075479A1/en not_active Ceased
- 2020-10-15 SG SG11202011647SA patent/SG11202011647SA/en unknown
- 2020-10-15 MX MX2022003911A patent/MX2022003911A/es unknown
- 2020-10-15 TW TW109135664A patent/TWI856193B/zh active
- 2020-10-15 CN CN202080085493.7A patent/CN114829604B/zh active Active
- 2020-10-15 EP EP20877556.9A patent/EP4045534A4/en active Pending
- 2020-10-15 CA CA3153207A patent/CA3153207A1/en active Pending
-
2022
- 2022-03-21 IL IL291557A patent/IL291557A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7628796B2 (ja) | 2025-02-12 |
| CN114829604A (zh) | 2022-07-29 |
| BR112022006014A2 (pt) | 2022-07-12 |
| CN114829604B (zh) | 2024-12-06 |
| TW202124455A (zh) | 2021-07-01 |
| JP2021063075A (ja) | 2021-04-22 |
| SG11202011647SA (en) | 2021-05-28 |
| TWI856193B (zh) | 2024-09-21 |
| CA3153207A1 (en) | 2021-04-22 |
| IL291557A (en) | 2022-05-01 |
| MX2022003911A (es) | 2022-04-20 |
| US20240092889A1 (en) | 2024-03-21 |
| EP4045534A1 (en) | 2022-08-24 |
| KR20220082698A (ko) | 2022-06-17 |
| WO2021075479A1 (en) | 2021-04-22 |
| EP4045534A4 (en) | 2023-11-15 |
| AU2020368745A1 (en) | 2022-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR120232A1 (es) | Un anticuerpo, una composición farmacéutica y un método | |
| ES2689080T3 (es) | Anticuerpos que se unen a TL1A y sus usos | |
| CO2019000968A2 (es) | Anticuerpos anti-virus del zika y métodos de uso | |
| CO2019012143A2 (es) | Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| EA201792273A1 (ru) | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела | |
| MX2025010757A (es) | Formulacion farmaceutica de ph bajo | |
| CL2017002686A1 (es) | Métodos para tratar o prevenir dolor de cabeza por migraña | |
| CO2018002360A2 (es) | Anticuerpos biespecíficos contra el a-beta humano y el receptor de transferrina humano y métodos de uso | |
| MX2021012769A (es) | Anticuerpos bloqueadores cd73. | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| PE20160690A1 (es) | Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos | |
| MX2016015263A (es) | Anticuerpos humanos frente a la proteina de anclaje del coronavirus causante del sindrome respiratorio de oriente medio. | |
| MX2018000347A (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
| EA201791754A1 (ru) | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ | |
| MX384790B (es) | Anticuerpos anti-tau humanizados. | |
| MX2019008736A (es) | Anticuerpos anti-virus del dengue y usos de los mismos. | |
| PE20191487A1 (es) | Anticuerpos anti-gitr y metodos de uso de los mismos | |
| BR112019001206A2 (pt) | anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss) | |
| MX375402B (es) | Nuevo anticuerpo anti-dengue de espectro completo. | |
| MX368228B (es) | Anticuerpos que se unen específicamente a her2. | |
| EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
| MX2017009680A (es) | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). | |
| MX2018005589A (es) | Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas. | |
| CL2022000230A1 (es) | Anticuerpos anti-ms4a4a y métodos de uso de los mismos | |
| EA201891529A1 (ru) | Композиции и способы обнаружения и лечения рака яичников |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |